scholarly journals Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model

2016 ◽  
Vol 312 ◽  
pp. 93-101 ◽  
Author(s):  
Ceren Sahin ◽  
Nazanin Doostdar ◽  
Joanna C. Neill
1993 ◽  
Vol 71 (5-6) ◽  
pp. 321-325 ◽  
Author(s):  
Morikuni Takigawa ◽  
Hiroshi Maeda ◽  
Kenichi Ueyama ◽  
Hidefumi Tominaga ◽  
Kei Matsumoto

The effect of long-term methamphetamine (MAP) treatment on intracranial self-stimulation of the lateral hypotholamus and locomotor traces was assessed. An attempt was made to provide a useful animal model for understanding anhedonia, stereotypy, and reoccurrence of liability, which are analogous to symptoms of schizophrenia. The frequency of intracranial self-stimulation (ICSS) as used as a measure of the animals' "hedonic–anhedonic" state. Following long-term MAP treatment (3 mg/kg), rats gradually showed stereotyped behavior, and became inactive and unresponsive to ICSS. These behavioral changes and decreased ICSS lasted several weeks after cessation of chronic MAP treatment and seemed to suggest post-MAP chronic psychosis and (or) anhedonia, two of the negative symptoms of schizophrenia. The traces of rat behavior affected by chronic MAP treatment were classified into three types, peripheral, mixed, and fixed, occurring in a dose-dependent manner. Reverse tolerance, similar to the reoccurrence of schizophrenic symptoms, was observed as a fixed stereotypy associated with loss of ICSS. These abnormal phenomena were suppressed by pretreatment with haloperidol. In the present study, the combination of ICSS and locomotor trace affected by chronic MAP treatment was proposed as an animal model of schizophrenia and as a useful technique for gauging the effect of neuroleptics.Key words: self-stimulation, anhedonia, stereotypy, reverse tolerance, animal disease model, schizophrenia, methamphetamine.


Author(s):  
Fokko J. Bosker ◽  
Anatoliy V. Gladkevich ◽  
Charmaine Y. Pietersen ◽  
Krista A. Kooi ◽  
Petra L. Bakker ◽  
...  

2012 ◽  
Vol 37 (7) ◽  
pp. 1699-1707 ◽  
Author(s):  
Ryan D Ward ◽  
Eleanor H Simpson ◽  
Vanessa L Richards ◽  
Gita Deo ◽  
Kathleen Taylor ◽  
...  

2007 ◽  
Vol 61 (7) ◽  
pp. 865-872 ◽  
Author(s):  
Purificación Tejedor-Real ◽  
Mar Sahagún ◽  
Nicole Faucon Biguet ◽  
Jacques Mallet

2010 ◽  
Vol 20 ◽  
pp. S500-S501
Author(s):  
B. Langen ◽  
D. Zschaber ◽  
H. Stange ◽  
T. Hage ◽  
N. Brandon ◽  
...  

2011 ◽  
Vol 69 (10) ◽  
pp. 928-935 ◽  
Author(s):  
Eleanor H. Simpson ◽  
Christoph Kellendonk ◽  
Ryan D. Ward ◽  
Vanessa Richards ◽  
Olga Lipatova ◽  
...  

2021 ◽  
Vol 11 (7) ◽  
pp. 917
Author(s):  
Suzanne Estaphan ◽  
Alexandrina Curpan ◽  
Dalia Khalifa ◽  
Laila Rashed ◽  
Andrei Ciobica ◽  
...  

While animal models for schizophrenia, ranging from pharmacological models to lesions and genetic models, are available, they usually mimic only the positive symptoms of this disorder. Identifying a feasible model of chronic schizophrenia would be valuable for studying the possible underlying mechanism and to investigate emerging treatments. Our hypothesis starts from the observation that combining ketamine with isolation could result in long-lasting neuro-psychological deficits and schizophrenia-like features; thus, it could probably be used as the first model of chronic schizophrenia that emphasizes the characteristic of having a multifactorial etiology. By the means of this study, we investigated the effects of ketamine administration combined with isolation in inducing schizophrenia-like symptoms in male albino rats and the brain reactive oxygen species levels. Our results showed that the number of lines crossings in the open field test, the number of open arm entries in the elevated plus maze, and the spontaneous alternations percentage in the Y-maze were significantly lower in the ketamine + isolation group compared to both the control and ketamine + social housing group (p < 0.05). Furthermore, the ketamine + isolation intervention significantly increased the MDA levels and decreased the GPx levels both in the hippocampus and the cortex of the rats. In addition, our premise of creating a model capable of exhibiting both positive and negative symptoms of schizophrenia was also based on adding the aripiprazole treatment to a group of rats. Therefore, we compared the ketamine + social isolation group with the ketamine + social isolation + aripiprazole group in order to attempt to discover if the antipsychotic drug would significantly decrease the potential positive schizophrenia-like symptoms induced by social isolation and ketamine. Given that we obtained significant results, we cautiously presume that this might be an important step in developing our animal model capable of illustrating both positive and negative symptoms of schizophrenia. This study could be a first step towards the creation of a complex animal model capable of exhibiting the multifactorial origin and manifestation of schizophrenia.


Sign in / Sign up

Export Citation Format

Share Document